HOTH

Hoth Therapeutics, Inc. - Common Stock (HOTH)

About Hoth Therapeutics, Inc. - Common Stock (HOTH)

Hoth Therapeutics, Inc. engages in the development of new generation therapies for dermatological disorders. Its product pipeline focuses on potential treatments for indications including atopic dermatitis (also known as eczema), chronic wounds, psoriasis, asthma, and acne. It offers the BioLexa Platform, a drug compound platform for the treatment of eczema. The company was founded by Robbie Knie, Matthew D. Eitner, and James Ahern on May 16, 2017 and is headquartered in New York, NY.

Details

Daily high

$1.33

Daily low

$1.23

Price at open

$1.31

52 Week High

$3.80

52 Week Low

$0.58

Market cap

17.7M

Dividend yield

0.00%

Volume

351,876

Avg. volume

2.9M

P/E ratio

-1.17

Hoth Therapeutics, Inc. - Common Stock News